Open AccessNew treatment of hepatitis C (Direct Acting Antiviral)
Author(s) -
Mohsen Akhondi-Meybodi
Publication year - 2019
Publication title -
majallah-i dānishgāh-i 'ulūm-i pizishkī-i shahīd ṣadūqī yazd/majallah-i dānishgāh-i 'ulūm-i pizishkī va khadamāt-i bihdāshtī-darmānī shahīd ṣadūqī yazd
Language(s) - English
Resource type - Journals
eISSN - 2228-5741
pISSN - 2228-5733
DOI - 10.18502/ssu.v27i5.1519
Subject(s) - medicine , liver disease , hepatitis c virus , disease , chronic hepatitis , hepatitis c , drug , intensive care medicine , chronic liver disease , hepatitis , immunology , virology , virus , pharmacology , cirrhosis
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention, recently in Iran new drug direct Acting agent (DAA) was developed that may be equivalent to original drugs that will hope to treat HCV and eliminated HCV in future